Sovaldi makes blockbuster history, ignites drug pricing unrest.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Cambodia's Imminent Graduation from Least Developed Country Status: What Will be the Impact of the TRIPS Agreement on Access to HIV and Hepatitis C Medicines in Cambodia?International journal of social determinants of health and health services · 2024
   Article
2. The potential impact of the Comprehensive and Progressive Agreement for Prans-Pacific Partnership on Thailand's hepatitis C treatment program.Globalization and health · 2024
   Article
3. Public funding for transformative drugs: the case of sofosbuvir.Drug discovery today · 2021
   Review
4. Why High Drug Pricing Is A Problem for Research Ethics.Journal of bioethical inquiry · 2020
   Article
5. The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration.Applied health economics and health policy · 2019
   Observational
6. DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS.Journal of health & biomedical law · 2018
   Article
7. Drugmakers accused of exploiting orphan drug incentives, fueling price problem.Nature biotechnology · 2017
   Article
8. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.Frontiers in pharmacology · 2016
   Article
9. $1-million price tag set for Glybera gene therapy.Nature biotechnology · 2015
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as